Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report

We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance statu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Luigi, Cimino, Giuseppe, Gozzi, Elisa, Sinjari, Marsela, Brandi, Martina, Ceddia, Serena, Cosimati, Antonella, Raimondi, Lucrezia, Fontana, Antonella, Filippi, Luca, Bagni, Oreste, Spinelli, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077606/
https://www.ncbi.nlm.nih.gov/pubmed/33976646
http://dx.doi.org/10.1159/000514979
_version_ 1783684909818183680
author Rossi, Luigi
Cimino, Giuseppe
Gozzi, Elisa
Sinjari, Marsela
Brandi, Martina
Ceddia, Serena
Cosimati, Antonella
Raimondi, Lucrezia
Fontana, Antonella
Filippi, Luca
Bagni, Oreste
Spinelli, Gian Paolo
author_facet Rossi, Luigi
Cimino, Giuseppe
Gozzi, Elisa
Sinjari, Marsela
Brandi, Martina
Ceddia, Serena
Cosimati, Antonella
Raimondi, Lucrezia
Fontana, Antonella
Filippi, Luca
Bagni, Oreste
Spinelli, Gian Paolo
author_sort Rossi, Luigi
collection PubMed
description We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide.
format Online
Article
Text
id pubmed-8077606
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-80776062021-05-10 Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report Rossi, Luigi Cimino, Giuseppe Gozzi, Elisa Sinjari, Marsela Brandi, Martina Ceddia, Serena Cosimati, Antonella Raimondi, Lucrezia Fontana, Antonella Filippi, Luca Bagni, Oreste Spinelli, Gian Paolo Case Rep Oncol Case Report We report a case of an elderly patient with metastatic castration-resistant prostate cancer, initially treated with abiraterone acetate (1,000 mg/day) combined with LH-RH antagonist, prednisone (10 mg/day), and zoledronic acid to manage bone metastases. In consideration of his poor performance status, radiological and biochemical progression of the disease, we decided to switch abiraterone to enzalutamide (160 mg/day). Due to adverse events, we reduced enzalutamide to a dose of 80 mg/day. Currently, the disease is under control despite the use of a low dose of enzalutamide. S. Karger AG 2021-03-31 /pmc/articles/PMC8077606/ /pubmed/33976646 http://dx.doi.org/10.1159/000514979 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Rossi, Luigi
Cimino, Giuseppe
Gozzi, Elisa
Sinjari, Marsela
Brandi, Martina
Ceddia, Serena
Cosimati, Antonella
Raimondi, Lucrezia
Fontana, Antonella
Filippi, Luca
Bagni, Oreste
Spinelli, Gian Paolo
Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
title Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
title_full Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
title_fullStr Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
title_full_unstemmed Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
title_short Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report
title_sort stunning response with low-dose enzalutamide after abiraterone acetate failure in a patient diagnosed with metastatic castration-resistant prostate cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077606/
https://www.ncbi.nlm.nih.gov/pubmed/33976646
http://dx.doi.org/10.1159/000514979
work_keys_str_mv AT rossiluigi stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT ciminogiuseppe stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT gozzielisa stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT sinjarimarsela stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT brandimartina stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT ceddiaserena stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT cosimatiantonella stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT raimondilucrezia stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT fontanaantonella stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT filippiluca stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT bagnioreste stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport
AT spinelligianpaolo stunningresponsewithlowdoseenzalutamideafterabirateroneacetatefailureinapatientdiagnosedwithmetastaticcastrationresistantprostatecanceracasereport

Ejemplares similares